SUDA signs Licence and Distribution Agreement with STADA
Filed with ASX · · 3 pages · English
Arovella Therapeutics Limited on 6ix
Story so far
Earlier from Arovella Therapeutics
- ZolpiMist Update
- iNKT cell therapy platform update
- SUDA appoints new cell and gene therapy manufacturing expert
- Disclosure Document Prospectus $3.65m
- SUDA Placement Raises $3.65m
Later from Arovella Therapeutics
- Dr Reuben Benjamin Appointed to SUDA iNKT Cell Therapy SAB
- GM presentation
- Chile Ministry of Health Approval Granted for ZolpiMist
- Arovella licences novel monoclonal antibody from MD Anderson
- AGM FY21 Presentation
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics